Absci (ABSI) Non-Current Deferred Tax Liability (2021 - 2024)
Absci's (ABSI) quarterly Non-Current Deferred Tax Liability came in at $175000.0 in Q3 2024, down 29.72% year-on-year from $249000.0 in Q4 2023, and little changed quarter-over-quarter from $175000.0 in Q2 2024.
Absci (ABSI) Non-Current Deferred Tax Liability (2021 - 2024) Analysis & Trends
Absci has disclosed Non-Current Deferred Tax Liability across 4 years of filings, most recently posting $175000.0 for Q3 2024.
- Non-Current Deferred Tax Liability for Q3 2024 came in at $175000.0, down 29.72% year-over-year; the trailing twelve-month figure through Sep 2024 was $175000.0 (down 29.72% YoY), and the FY2023 annual result was $186000.0, down 98.96% from the prior year.
- Non-Current Deferred Tax Liability came in at $175000.0 for Q3 2024 at Absci, roughly flat from $175000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $17.9 million in Q4 2022 to a low of $175000.0 in Q1 2024.
- The 4-year median for Non-Current Deferred Tax Liability is $496000.0 (2021), against an average of $2.3 million.
- Across the five-year window, Non-Current Deferred Tax Liability jumped 2308.61% in 2022 and plunged 98.96% in 2023, its largest moves.
- Absci's Non-Current Deferred Tax Liability stood at $743000.0 in 2021, then surged by 2308.61% to $17.9 million in 2022, then slumped by 98.96% to $186000.0 in 2023, then declined by 5.91% to $175000.0 in 2024.
- The last three Non-Current Deferred Tax Liability figures came in at $175000.0 (Q3 2024), $175000.0 (Q2 2024), and $175000.0 (Q1 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Absci | 1.13 Bn | 1.01 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 175,000.00 |
| Sep 30, 2024 | 175,000.00 |
| Jun 30, 2024 | 175,000.00 |
| Jun 30, 2024 | 175,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Mar 31, 2024 | 175,000.00 |
| Dec 31, 2023 | 186,000.00 |
| Dec 31, 2023 | 186,000.00 |
| Sep 30, 2023 | 249,000.00 |
| Sep 30, 2023 | 249,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Jun 30, 2023 | 223,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Dec 31, 2022 | 17.90 Mn |
| Dec 31, 2022 | 17.90 Mn |
| Sep 30, 2022 | 756,000.00 |
| Sep 30, 2022 | 756,000.00 |
| Jun 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 1.09 Mn |